Meloxicam:a selective COX-2 inhibitor non-steroidal anti-inflammatory drug

Bibliography

• VANE JR: Inhibition of prostaglandin synthesis as a mechanism o f action of aspirin-like drugs. Nature (1971) 231:232–235.
   Web of Science ®Google Scholar
• PAIRET M, ENGELHARDT G: Distinct is oforms (COX-1 and COX-2) of cyclo-oxygenase: possible physiological and therapeutic implications. Fundam. Clin. Pharmacol. (1996) 10:1–15.
   PubMed Web of Science ®Google Scholar
• LARKAI EN, LACEY SMITH J, LIDSKY MD, SESSOMS SL, GRAHAM DY: Dyspepsia in NSAID users: the size of the problem../. Clin. Gastroenterol. (1989) 11:158–162.
   PubMed Web of Science ®Google Scholar
• GIERCKSKY K-E, HUSEBY G, RUGSTAD H-E: Epidemiol-ogy of NSAID-related gastrointestinal side-effects. Scand. j Gastroenterol (1989) 24\(Suppl. 163):3–8.
   Google Scholar
• FRIES JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. (1991) 18\(Suppl. 28):6–10.
   Google Scholar
• GARCIA RODRIGUEZ LA, JICK H: Risk of upper gastroin-testinal bleeding and perforation associated with indi-vidual non-steroidal anti-inflammatory drugs. Lancet (1994) 343:769–772.
   PubMed Web of Science ®Google Scholar
• FRIES JF, WILLIAMS CA, BLOCH DA: The relative toxicity of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. (1991) 34:1353–1360.
   PubMed Web of Science ®Google Scholar
• LANGMAN MJS, WEIL J, WAINWRIGHT P et al.: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 343:1075–1078.
   PubMed Web of Science ®Google Scholar
• HENRY D, LIM LL-Y, GARCIA RODRIGUEZ LA et al: Vari-ability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: re-sults of a collaborative meta-analysis. Br. Med. J. (1996) 312:1563–1566.
   PubMed Web of Science ®Google Scholar
• FLOWER RJ, VANE JR: Inhibition of prostaglandin syn-thetase in brain explains the anti-pyretic activity of paracetamol -acetamidophe nol) . Nature (19 7 2) 240:410–411.
   Google Scholar
• RAZ A, WYCH A, SIEGEL N, NEEDLEMAN P: Regulation of fibroblast cyclo-oxygenase synthesis by interleukin-1. J. Biol. Chem. (1988) 263:3022–3025.
   PubMed Web of Science ®Google Scholar
• WONG WYL, RICHARDS JS: Evidence for two antigeni-cally distinct molecular weight variants of pro-staglandin H synthase in the rat ovary. Mol. Endocrinol (1991) 5:1269–1279.
   PubMed Web of Science ®Google Scholar
• (MANION MK, SADOWSKI HB, WINN V, YOUNG DA: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclo-oxygenase-related protein. J. Biol. Chem. (1991) 266:23261–23267.
   PubMed Web of Science ®Google Scholar
• XIE W, CHIPMAN JG, ROBERTSON DL, ERIKSON RL, SIM-MONS DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA (1991) 88:1692–1696.
   Web of Science ®Google Scholar
• VANE JR: Towards a better aspirin. Nature (1994) 367:215–216.
   PubMed Web of Science ®Google Scholar
• HLA T, RISTIMAKI A, APPLEBY S, BARRIOCANAL JG: Cy-clo-oxygenase gene expression in inflammation and angiogenesis. Ann. NY Acad. Sci. (1993) 696:197–204.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ZWEIFEL BS, MANNING PT et al: Selective inhibition of inducible cyclo-oxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Nall Acad. ScL USA (1994) 91:3228–3232.
   PubMed Web of Science ®Google Scholar
• VANE JR, MITCHELL JA, APPLETON I et al: Inducible isoforms of cyclo-oxygenase and nitric-oxide synthase in inflammation. Proc. Natl. Acad. Sci. USA (1994) 91:2046–2050.
   PubMed Web of Science ®Google Scholar
• CAVANAUGH PF, Jr., MCDONALD JS, PAVELIC L et al.:Immunohistochemical localization of prostaglandin H synthase isoenzyme proteins in the gingival tissue of patients with periodontitis. Immunopharmacology (1995) 3:109–119.
   Google Scholar
• PICOT D, LOLL PJ, GARAVITO RM: The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (1994) 367:243–249.
   PubMed Web of Science ®Google Scholar
• BROWNER MF: X-ray crystal structure of human cyclo-oxygenase-2. In: New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Vane J, Botting J, Botting R (Eds.), Kluwer Academic Publishers, Dordrecht, Boston, Lon-don (1996).
   Google Scholar
• LANEUVILLE 0, BREUER DK, DEWITT DL et al.: Differen-tial inhibition of human prostaglandin endoperoxide H synthases -1 and-2 by nonsteroidal anti-inflammatory drugs. 1 Pharmacol Exp. Ther. (1994) 271:927–934.
   Google Scholar
• MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR: Selectivity of nonsteroidal anti-in-flammatory drugs as inhibitors of constitutive and inducible cyclo-oxygenase. Proc. Natl. Acad. ScL USA (1994) 90:11693–11697.
   Web of Science ®Google Scholar
• ENGELHARDT G, BOGEL R, SCHNITZER C, UTZMANN R: Meloxicam: influence on arachidonic acid metabolism. Part I: In vitro findings. Biochem. Pharmacol (1996) 51:21–28.
   PubMed Web of Science ®Google Scholar
• CHURCHILL L, GRAHAM AG, SHIH C-K et al: Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Immunopharmacology (1996) 4:125–135.
   Google Scholar
• O'NEILL GP, MANCINI JA, KARGMAN S et al: Overexpres-sion of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hy-droxyeicosatetraenoic acid. MoL PharmacoL (1994) 45:245–254.
   PubMed Web of Science ®Google Scholar
• PATRIGNANI P, PANARA MR, GRECO A et al: Biochemicaland pharmacological characterization of the cyclo-oxy-genase activity of human blood prostaglandin endop-eroxide synthas es. J. Pharmacol Exp. Ther. (1994) 271:1705–1712.
   PubMed Web of Science ®Google Scholar
• GLASER K, SUNG M-L, O'NEILL K et al.: Etodolac selec-tively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus PGHS-1. Eur. J. Pharmacol. (1995) 281:107–111.
   Google Scholar
• OGINO K, HARADA Y, KAWAMURA Metal.:An inhibitoryeffect of meloxicam, a novel non-steroidal anti-inflam- matory drug, on COX-2. Jpn. j Pharmacol (1996) 71 (Suppl. 1):304P.
   Google Scholar
• PAIRET M, LIDBURY PS, ENGELHARDT G, TRUMMLITZ G,VANE JR. Meloxicam: cyclo-oxygenase selectivity, anti-inflammatory activity and gastric and renal safety. Inflarnm. Res. (1995) 44\(Suppl. 3):S274.
   Google Scholar
• PATRIGNANI P, PANARA M, SAN TINT G et al: Differentialinhibition of the cyclo-oxygenase activity of pro-staglandin endoperoxide synthase isoenzymes in vitro and ex vivo in man. 10th International Conference on Prostaglandins and Related Compounds (1996) 55(1) P115.
   Google Scholar
• PANARA M, GRECO A, SANTINI G etal: Effects of the novelanti-inflammatory compounds Is142-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido -6- (2,4-difluorothiophenyl) -1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide syn-thases. Br. J. Pharmacol (1995) 116:2429–2434.
   PubMed Web of Science ®Google Scholar
• MEADE EA, SMITH WL, DEWITT DL: Differential inhibi-tion of prostaglandin endoperadde synthase (cyclo-oxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1993) 268:6610–6614.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT G, BOGEL R, SCHNITZLER C, UTZMANN R: Meloxicam: influence on arachidonic acid metabolism. Part IL hi vivo findings. Biochem. Pharmacol (1996) 51:29–38.
   PubMed Web of Science ®Google Scholar
• PAIRET M, ENGELHARDT G: Differential inhibition ofCOX-1 and COX-2 in vitro and pharmacological profile in vivoofNSAIDs. In: Improved Non-Steroidal Anti-Inflam-matory Drugs - COX-2 Enzyme Inhibitors. Vane J, Botting J, Botting R (Eds.), Kluwer Academic Publishers, Dordrecht, Boston, London (1996):103–119.
   Google Scholar
• STICHTENOTH DO, GUTZKI F-M, WAGNER B, TSIKAS D,FROLICH JC: Meloxicam, a new NSAID, is cyclo-oxy-genas e-1 sparing in humans in viva j Invest Med. (1996) 44:297A.
   Google Scholar
• PATOIA L, SANTUCCI L, FURNO P etal.: A 4-week, double-blind, parallel-group study to compare the gastrointes-tinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br. J. Rheumatol. (1996) 35\(Suppl. 1):61–67.
   Google Scholar
• BEVIS PFR, BIRD HA, LAPHAM G: An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impair-ment. Br. J. Rheumatol. (1996) 35\(Suppl. 0:56–60.
   Google Scholar
• TORCK D, ROTH W, BUSCH U: A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheumatol. (1996) 35\(Suppl. 0:13–16.
   Google Scholar
• TORCK D, BUSCH U, HEINZEL G, NARJES H, NEHMIZ G: Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin. Drug. Invest. (1995) 9:270–276.
   Web of Science ®Google Scholar
• BUSCH U, ENGELHARDT G: Distribution of [14C] meloxi-cam in joints of rats with adjuvant arthritis. Drugs Exp. Clin. Res. (1990) 16:49–52.
   PubMedGoogle Scholar
• SCHMID J, BUSCH U, TRUMMLITZ G: Meloxicam: metabo-lic profile and biotransformation products in the rat. Xenobiotica (1995) 25:1219–1236.
   PubMed Web of Science ®Google Scholar
• SCHMID J, KASCHKE S, PROX A, ENGELHARDT G: Biotransformation of me loxicam in man: metabolic pattern, isolation, structure elucidation and pharma-cological testing of a main metabolite. Exp. Toxic Pathol (1996) 48(5):387–388.
   Google Scholar
• SANDER 0, HUBNER G, TORCK D, DEGNER F, RAU R: Meloxicam pharmacokinetics in elderly compared to younger male and female patients with rheumatoid arthritis. Rheumatol Eur. (1995) 24 (Suppl. 3):221, Abstract D20.
   Google Scholar
• TCJRCK D, BOULTON-JONES M, NORTH N, HEINZEL G, NEHMIZ G: A Phase I study to determine the steady state pharmacokinetics of meloxicam 15 mg capsules in moderate, mild or no renal impairment. Rheumatol Eur. (1995) 24\(Suppl. 3):221, Abstract D17.
   Google Scholar
• BUSCH U, HEINZEL G, NARJES H et al.: Pharmacokinetics of meloxicam in patients with hepatic cirrhosis in comparison with healthy volunteers. Clin. Drug Invest. (1996) 11:97–107.
   Web of Science ®Google Scholar
• DEGNER F, HEINZEL G, NARJES H, TORCK D: The effect of meloxicam on the pharmacokinetics of B-ace-tyldigoxin. Br. J. Clin. Pharmacol (1995) 40:486–488.
   PubMed Web of Science ®Google Scholar
• HUBNER G, SANDER 0, DEGNER F, RAU R: Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients. Scand. J. Rheumatol (1994) Suppl. 98. Abstract 108.
   Google Scholar
• BUSCH U, HEINZEL G, NARJES H, NEHMIZ G: Interaction of meloxicam with cimetidine, Maalox or aspirin. j Clin. Pharmacol. (1996) 36:79–84.
   PubMed Web of Science ®Google Scholar
• MOLLER FO, SCHALL R, DEVAAL AC eta].: No interaction of meloxicam with either single or multiple repeated doses of furosemide. Eur. J. Clin. Pharmacol (1995) 48:247–251.
   Google Scholar
• TORCK D, SU CAPF, HEINZEL G et al.: Lack of interaction between meloxicam and warfarin in healthy volun-teers. Eur. j Clin. Pharmacol In press.
   Google Scholar
• LUND B, DISTEL M, BLUHMKI DM: A double -blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis of the knee. Scand. J. Rheumatol. (1994) Suppl. 98. Abstract 117.
   Google Scholar
• LINDEN B, DISTEL M, BLUHMKI E: A double-blind study to compare the efficacy and safety of me loxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol (1996) 35\(Suppl. 0:35–38.
   Google Scholar
• HOSIE J, DISTEL M, BLUHMKI E: A six month, double-blind study comparing meloxicam 15 mg with piroxi-cam 20 mg in osteoarthritis. Rheumatology in Europe (1995) 24 (Suppl. 3):325, Abstract E50.
   Google Scholar
• GOEI THE H, LUND B, DISTEL, BLUHMKI E: A double-blind, randomised trial comfaring meloxicam with diclofenac in osteoarthritis. Rhetffnatology in Europe (1995) 24 (Suppl. 3):325, Abstract E51.
   Google Scholar
• HOSIE J, DISTEL M, BLUHMKI E: Meloxicam inosteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br. Rheumatol. (1996) 35 (Sup pl. 1) 39–43.
   Google Scholar
• LEMMEL EM, BOLTON W, BURGOS-VARGAS R et al.: Adouble-blind placebo-controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis. Scand. J. Rheumatol. (1994) Suppl. 98. Abstract 111.
   Google Scholar
• HUSKISSON EC, NARJES H, BLUHMKI E, DEGNER F: Com-parison of meloxicam 15 mg and pirmdcam 20 mg in a 3-week, double-blind trial in RA. Eighth APLAR Congress of Rheumatology (1996). Abstract 351.
   Google Scholar
• WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et aL: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol (1996) 35 (Suppl. 1):22–28.
   Google Scholar
• AUVINET B, ZILLER R, APPELBOOM T, VÉLICITAT P: Com-parison o f the onset and intensity of action of intra mus-cular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. (1995) 17:1078–1090.
   PubMed Web of Science ®Google Scholar
• BOSCH H-C, HETTICH M, DEGNER FL: Efficacy and toler-ability of intramuscular and oral meloxicam: a compari- son with pirwdcam in acute lumbago. Rheumatol Eur. (1996) 25 (Suppl. 1):Abstract 431.
   Google Scholar
• COLBERG K, HETTICH M, SIGMUND R, DEGNER FL: The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. (1996) 13:363–377.
   PubMed Web of Science ®Google Scholar
• DISTEL M, MUELLER C, BLUHMKI E: Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology (1996) 4:71–81.
   Google Scholar